Literature DB >> 6281293

Escape from mineralocorticoid excess: the role of angiotensin II.

J Biollaz, J Dürr, H R Brunner, M Porchet, H Gavras.   

Abstract

Escape from the sodium-retaining action of mineralocorticoids coincides with the suppression of plasma renin and angiotensin II levels. The purpose of this study was to evaluate whether blockade of the renin system accelerates this escape. Eight male normotensive volunteers, aged 24--33 yr, were maintained during two subsequent periods of 12 days each, separated by 3--4 weeks, on a constant intake of sodium and potassium of 140 mmol/day. During both periods, fludrocortisone acetate (0.2 mg) was administered orally three times a day on days 4--12. In addition, on days 3--12, either a converting enzyme inhibitor (MK 421;20 mg orally, twice daily) or a placebo was added in double blind fashion and randomized sequence. During both periods, blood pressures were similar; they tended to increase slightly toward day 12. The weight increase did not differ between the two periods. With MK 421, angiotension II levels were significantly lower than with placebo on days 3--6 (P less than 0.001). On the same days, PRA was increased due to converting enzyme blockade. Despite the significantly different angiotensin II levels on days 3--6, daily urinary sodium excretion on all individual days as well as cumulative sodium balance were the same during both periods. Therefore, we could find no evidence in man that suppression of circulating angiotensin II levels is causally related to escape from mineralocorticoid excess.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281293     DOI: 10.1210/jcem-54-6-1187

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection.

Authors:  Fernando L Martin; Paul M McKie; Alessandro Cataliotti; S Jeson Sangaralingham; Josef Korinek; Brenda K Huntley; Elise A Oehler; Gerald E Harders; Tomoko Ichiki; Sarah Mangiafico; Karl A Nath; Margaret M Redfield; Horng H Chen; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

Review 2.  Angiotensin II-receptor antagonist in the treatment of hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Erika Pagannone
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 3.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

4.  Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway.

Authors:  N Yokota; B G Bruneau; M L Kuroski de Bold; A J de Bold
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

Authors:  Massimo Volpe; Carmine Savoia
Journal:  Integr Blood Press Control       Date:  2012-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.